We are excited to announce that Biocytogen will exhibit at the 2026 BioPacific Conference on September 19th in South San Francisco, CA. As CABS' flagship annual conference, BioPacific brings together biotechnology professionals from communities across the Pacific Rim countries and beyond. Visit our booth to discover how Biocytogen's fully human antibody discovery platforms and humanized mouse models support the next generation of therapeutic development.
What is CABS?
The BioPacific Conference is the flagship annual conference of the Chinese-American BioPharmaceutical Society (CABS). It brings together scientists, executives, and biopharmaceutical professionals from the Pacific Rim to discuss the latest advances in life sciences, emerging industry trends, and opportunities for collaboration. Through scientific presentations, panel discussions, and networking, the conference is a platform for attendees to explore innovation and opportunities across the field.
Event Overview
Date: September 19th, 2026
Venue: South San Francisco Conference Center, 255 S Airport Blvd, South San Francisco, CA 94080
Event Schedule
For more information, please refer to the CABS website.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
